Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 2/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | SPR | P35270 | 3/20 | 0.35 |
| ▸ | NAMPT | P43490 | 3/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL700241 | 0.96 | JAK3 (0.43) | JAK3GRIN2BGRIN2CSPRNAMPT | |
| Hydrochloric Acid SCHEMBL19582520 | 0.94 | JAK3 (0.43) | JAK3GRIN2BGRIN2CSPRNAMPT | |
| SCHEMBL14762409 | 0.93 | JAK3 (0.42) | JAK3GRIN2BGRIN2CSPRNAMPT | |
| SCHEMBL15286428 | 0.91 | JAK3 (0.46) | JAK3GRIN2BGRIN2CSPRNAMPT | |
| Hydrochloric Acid SCHEMBL15288269 | 0.90 | JAK3 (0.45) | JAK3GRIN2BGRIN2CSPRNAMPT | |
| SCHEMBL1771960 | 0.87 | JAK3 (0.42) | JAK3GRIN2BGRIN2CSPRNAMPT | |
| SCHEMBL34473824 | 0.87 | JAK3 (0.42) | JAK3GRIN2BGRIN2CSPRNAMPT | |
| Oxalic Acid SCHEMBL31627257 | 0.87 | JAK3 (0.42) | JAK3GRIN2BGRIN2CSPRCNR2 | |
| SCHEMBL31450504 | 0.87 | JAK3 (0.42) | JAK3GRIN2BGRIN2CSPRNAMPT | |
| SCHEMBL3706160 | 0.86 | JAK3 (0.38) | JAK3GRIN2BGRIN2CSPRCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029551-B1 | PYRIDINONE AND PYRIDAZINONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | MSD ITALIA SRL (IT) | 2018-10-31 | — | — | EP | disclosed |
| US-8188084-B2 | Pyridinone and pyridazinone derivatives as inhibitors of poly (ADP-ribose) polymerase (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA. (IT) | 2012-05-29 | — | — | US | disclosed |
| US-20090176765-A1 | Pyridinone and Pyridazinone Derivatives as Inhibitors of Poly (Adp-Ribose) Polymerase (Parp) | MSD ITALIA S.R.L. (IT) | 2009-07-09 | — | — | US | disclosed |
| EP-2029551-A2 | PYRIDINONE AND PYRIDAZINONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007138351-A2 | PYRIDINONE AND PYRIDAZINONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176765-A1 | Pyridinone and Pyridazinone Derivatives as Inhibitors of Poly (Adp-Ribose) Polymerase (Parp) | PARP1, PARP2, PARP3 | JAK3 1424/4885GRIN2B 3470/4885GRIN2C 4309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.